Impact of famotidine on blood carnitine levels and L-carnitine supplementation dose in tube-fed patients with severe motor and intellectual disabilities.

<i>Introduction:</i> Carnitine is essential for mitochondrial fatty acid transport and energy production. Tube-fed patients with severe motor and intellectual disabilities (SMID) receiving carnitine-free enteral nutrition are at increased risk of carnitine deficiency. Famotidine, used to treat gastroesophageal reflux disease (GERD), inhibits carnitine transport <i>in vitro</i>, but its clinical impact remains unclear. This study investigated the effect of famotidine on blood carnitine concentrations and L-carnitine supplementation requirements in tube-fed patients with SMID. <i>Methods:</i> A retrospective observational study including patients receiving exclusive enteral nutrition and L-carnitine supplementation was conducted at the Tokyo Metropolitan Tobu Medical Center. Blood carnitine level and L-carnitine dose were compared between famotidine users and non-users. <i>Results:</i> Among 25 subjects (45 data points), famotidine users required significantly higher L-carnitine doses to maintain normal free carnitine levels than did non-users (22.0 ± 4.0 mg/kg/day vs. 13.0 ± 2.8 mg/kg/day, respectively [p = 0.024]). A correlation between L-carnitine dose and free carnitine level was observed only among non-users of famotidine (correlation coefficient: 0.352). Additionally, 36.8% of famotidine users exhibited persistently low free carnitine levels despite supplementation, compared to 3.9% of non-users. <i>Conclusion:</i> Famotidine use was associated with increased L-carnitine supplementation requirements, likely due to impaired renal carnitine reabsorption. Routine monitoring of famotidine-treated patients may help prevent L-carnitine deficiency. Further studies should assess possible long-term effects and explore alternative GERD treatments that have minimal impact on carnitine metabolism. Expanding insurance coverage for carnitine testing could improve early detection and intervention.

Authors

Publication Details

Journal
PubMed
Published
2025-10-01
DOI
https://doi.org/10.1691/ph.2025.5570
Primary Topic
Metabolism and Genetic Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of famotidine on blood carnitine levels and L-carnitine supplementation dose in tube-fed patients with severe motor and intellectual disabilities.

Yoichi Urakawa, Shinji Hidaka, Motoki Arakawa, Nao Sato et al.
PubMed
Metabolism and Genetic Disorders
article

Impact of famotidine on blood carnitine levels and L-carnitine supplementation dose in tube-fed patients with severe motor and intellectual disabilities.

Yoichi Urakawa, Shinji Hidaka, Motoki Arakawa, Nao Sato, Yoshio Arai, K Funatsu
article en

Abstract

<i>Introduction:</i> Carnitine is essential for mitochondrial fatty acid transport and energy production. Tube-fed patients with severe motor and intellectual disabilities (SMID) receiving carnitine-free enteral nutrition are at increased risk of carnitine deficiency. Famotidine, used to treat gastroesophageal reflux disease (GERD), inhibits carnitine transport <i>in vitro</i>, but its clinical impact remains unclear. This study investigated the effect of famotidine on blood carnitine concentrations and L-carnitine supplementation requirements in tube-fed patients with SMID. <i>Methods:</i> A retrospective observational study including patients receiving exclusive enteral nutrition and L-carnitine supplementation was conducted at the Tokyo Metropolitan Tobu Medical Center. Blood carnitine level and L-carnitine dose were compared between famotidine users and non-users. <i>Results:</i> Among 25 subjects (45 data points), famotidine users required significantly higher L-carnitine doses to maintain normal free carnitine levels than did non-users (22.0 ± 4.0 mg/kg/day vs. 13.0 ± 2.8 mg/kg/day, respectively [p = 0.024]). A correlation between L-carnitine dose and free carnitine level was observed only among non-users of famotidine (correlation coefficient: 0.352). Additionally, 36.8% of famotidine users exhibited persistently low free carnitine levels despite supplementation, compared to 3.9% of non-users. <i>Conclusion:</i> Famotidine use was associated with increased L-carnitine supplementation requirements, likely due to impaired renal carnitine reabsorption. Routine monitoring of famotidine-treated patients may help prevent L-carnitine deficiency. Further studies should assess possible long-term effects and explore alternative GERD treatments that have minimal impact on carnitine metabolism. Expanding insurance coverage for carnitine testing could improve early detection and intervention.

PubMedVol. 80(9)
Openalex Percentile: Top 64%
Metabolism and Genetic Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.